BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021 - April 2022
dc.contributor.author | Zambrano, Laura D. | |
dc.contributor.author | Newhams, Margaret M. | |
dc.contributor.author | Olson, Samantha M. | |
dc.contributor.author | Halasa, Natasha B. | |
dc.contributor.author | Price, Ashley M. | |
dc.contributor.author | Orzel, Amber O. | |
dc.contributor.author | Young, Cameron C. | |
dc.contributor.author | Boom, Julie A. | |
dc.contributor.author | Sahni, Leila C. | |
dc.contributor.author | Maddux, Aline B. | |
dc.contributor.author | Bline, Katherine E. | |
dc.contributor.author | Kamidani, Satoshi | |
dc.contributor.author | Tarquinio, Keiko M. | |
dc.contributor.author | Chiotos, Kathleen | |
dc.contributor.author | Schuster, Jennifer E. | |
dc.contributor.author | Cullimore, Melissa L. | |
dc.contributor.author | Heidemann, Sabrina M. | |
dc.contributor.author | Hobbs, Charlotte V. | |
dc.contributor.author | Nofziger, Ryan A. | |
dc.contributor.author | Pannaraj, Pia S. | |
dc.contributor.author | Cameron, Melissa A. | |
dc.contributor.author | Walker, Tracie C. | |
dc.contributor.author | Schwartz, Stephanie P. | |
dc.contributor.author | Michelson, Kelly N. | |
dc.contributor.author | Coates, Bria M. | |
dc.contributor.author | Flori, Heidi R. | |
dc.contributor.author | Mack, Elizabeth H. | |
dc.contributor.author | Smallcomb, Laura | |
dc.contributor.author | Gertz, Shira J. | |
dc.contributor.author | Bhumbra, Samina S. | |
dc.contributor.author | Bradford, Tamara T. | |
dc.contributor.author | Levy, Emily R. | |
dc.contributor.author | Kong, Michele | |
dc.contributor.author | Irby, Katherine | |
dc.contributor.author | Cvijanovich, Natalie Z. | |
dc.contributor.author | Zinter, Matt S. | |
dc.contributor.author | Bowens, Cindy | |
dc.contributor.author | Crandall, Hillary | |
dc.contributor.author | Hume, Janet R. | |
dc.contributor.author | Patel, Manish M. | |
dc.contributor.author | Campbell, Angela P. | |
dc.contributor.author | Randolph, Adrienne G. | |
dc.contributor.author | Overcoming COVID-19 Investigators | |
dc.contributor.department | Pediatrics, School of Medicine | |
dc.date.accessioned | 2023-08-09T15:39:21Z | |
dc.date.available | 2023-08-09T15:39:21Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Background: Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood. Methods: In a multicenter, case-control, public health investigation of children ages 5-18 years hospitalized from 1 July 2021 to 7 April 2022, we compared the odds of being fully vaccinated (2 doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression. Results: We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (adjusted OR [aOR]: .16; 95% CI: .10-.26), including among children ages 5-11 years (aOR: .22; 95% CI: .10-.52), ages 12-18 years (aOR: .10; 95% CI: .05-.19), and during the Delta (aOR: .06; 95% CI: .02-.15) and Omicron (aOR: .22; 95% CI: .11-.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR: .08; 95% CI: .03-.22) in 12-18-year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible case-patients were unvaccinated. Conclusions: Vaccination with 2 doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5-18 years. Most vaccine-eligible hospitalized patients with MIS-C were unvaccinated. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Zambrano LD, Newhams MM, Olson SM, et al. BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021 - April 2022. Clin Infect Dis. 2023;76(3):e90-e100. doi:10.1093/cid/ciac637 | |
dc.identifier.uri | https://hdl.handle.net/1805/34812 | |
dc.language.iso | en_US | |
dc.publisher | Oxford University Press | |
dc.relation.isversionof | 10.1093/cid/ciac637 | |
dc.relation.journal | Clinical Infectious Diseases | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | MIS-C | |
dc.subject | Vaccine effectiveness | |
dc.subject | Pfizer (BioNTech) | |
dc.subject | COVID-19 | |
dc.subject | Children | |
dc.title | BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021 - April 2022 | |
dc.type | Article | |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384630/ |